MX2021004976A - Anticuerpo fn14 antihumano. - Google Patents

Anticuerpo fn14 antihumano.

Info

Publication number
MX2021004976A
MX2021004976A MX2021004976A MX2021004976A MX2021004976A MX 2021004976 A MX2021004976 A MX 2021004976A MX 2021004976 A MX2021004976 A MX 2021004976A MX 2021004976 A MX2021004976 A MX 2021004976A MX 2021004976 A MX2021004976 A MX 2021004976A
Authority
MX
Mexico
Prior art keywords
human
antibody
seq
amino acid
acid sequence
Prior art date
Application number
MX2021004976A
Other languages
English (en)
Inventor
Misato Ito
Risa Kashiwagi
Masakatsu Kawakami
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of MX2021004976A publication Critical patent/MX2021004976A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Problema. Se proporciona un anticuerpo Fn14 antihumano que se une al Fn14 humano para inhibir una acción a través del Fn14 humano, evitando o tratar la caquexia por cáncer. Solución. Los inventores han realizado estudios sobre un anticuerpo Fn14 antihumano y han proporcionado un anticuerpo Fn14 antihumano que comprende una cadena pesada que consiste en la secuencia de aminoácidos de SEQ ID NO: 2 y una cadena ligera que consiste en la secuencia de aminoácidos de SEQ ID NO: 4.
MX2021004976A 2018-10-31 2019-10-30 Anticuerpo fn14 antihumano. MX2021004976A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018205995 2018-10-31
PCT/JP2019/042587 WO2020090892A1 (ja) 2018-10-31 2019-10-30 抗ヒトＦｎ１４抗体

Publications (1)

Publication Number Publication Date
MX2021004976A true MX2021004976A (es) 2021-06-15

Family

ID=70464144

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021004976A MX2021004976A (es) 2018-10-31 2019-10-30 Anticuerpo fn14 antihumano.

Country Status (17)

Country Link
US (1) US20210388096A1 (es)
EP (1) EP3875114A4 (es)
JP (1) JP7415939B2 (es)
KR (1) KR20210084473A (es)
CN (1) CN112930195B (es)
AR (1) AR123671A1 (es)
AU (1) AU2019369771A1 (es)
BR (1) BR112021008424A2 (es)
CA (1) CA3117930A1 (es)
CO (1) CO2021005768A2 (es)
IL (1) IL282650B1 (es)
JO (1) JOP20210093A1 (es)
MA (1) MA54097A (es)
MX (1) MX2021004976A (es)
SG (1) SG11202104463YA (es)
WO (1) WO2020090892A1 (es)
ZA (1) ZA202102879B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3207850A1 (en) 2021-01-13 2022-07-21 Astellas Pharma Inc. Multispecific antibody bonding to actriia, actriib, and fn14
WO2023062848A1 (en) * 2021-10-14 2023-04-20 Astellas Pharma Inc. Pharmaceutical composition comprising anti-human fnl4 antibody or antigen-binding fragment thereof for preventing or treating cancer

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
KR100337069B1 (ko) 1993-03-11 2002-10-11 사이단호진가가쿠오요비겟세이리요호오겐큐쇼 항-hiv모노클로날항체
EP2298333A3 (en) * 1999-12-20 2012-05-02 Immunex Corporation Tweak receptor
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
CA2597485A1 (en) * 2005-03-07 2006-09-14 Genentech, Inc. Methods and compositions for modulating tweak and fn14 activity
LT2460831T (lt) * 2005-05-27 2016-12-12 Biogen Ma Inc. Tweak rišantys antikūnai
KR20100053607A (ko) * 2007-08-03 2010-05-20 패시트 바이오테크 코포레이션 항-ｔｗｅａｋ 수용체 항체의 치료 용도
US20090324602A1 (en) * 2008-05-15 2009-12-31 Biogen Idec Ma Inc. Anti-fn14 antibodies and uses thereof
US8093006B2 (en) * 2009-04-02 2012-01-10 Hoffmann-La Roche Inc. Antibodies against human tweak and uses thereof
US8609818B2 (en) * 2011-03-10 2013-12-17 Omeros Corporation Generation of anti-FN14 monoclonal antibodies by ex-vivo accelerated antibody evolution
JP2014529597A (ja) 2011-08-23 2014-11-13 トランスバイオ リミテッド Ｆｎ１４結合性タンパク質及びその使用
JP2016000003A (ja) * 2013-04-19 2016-01-07 アステラス製薬株式会社 新規抗ヒトｔｗｅａｋ抗体
AU2014280174A1 (en) * 2013-06-14 2015-12-03 Bayer Pharma Aktiengesellschaft Anti-TWEAKR antibodies and uses thereof
EP3019874B1 (en) * 2013-07-09 2019-08-21 The Translational Genomics Research Institute Compositions and methods of screening for compounds that modulate activity at a tweak binding site on a crd of fn14

Also Published As

Publication number Publication date
AR123671A1 (es) 2023-01-04
BR112021008424A2 (pt) 2021-09-28
WO2020090892A1 (ja) 2020-05-07
IL282650B1 (en) 2024-05-01
KR20210084473A (ko) 2021-07-07
TW202035459A (zh) 2020-10-01
SG11202104463YA (en) 2021-05-28
JPWO2020090892A1 (ja) 2021-09-24
CN112930195A (zh) 2021-06-08
MA54097A (fr) 2022-02-09
AU2019369771A1 (en) 2021-06-03
IL282650A (en) 2021-06-30
CA3117930A1 (en) 2020-05-07
US20210388096A1 (en) 2021-12-16
JOP20210093A1 (ar) 2023-01-30
CN112930195B (zh) 2024-03-19
JP7415939B2 (ja) 2024-01-17
ZA202102879B (en) 2022-10-26
EP3875114A1 (en) 2021-09-08
EP3875114A4 (en) 2022-08-10
CO2021005768A2 (es) 2021-05-10

Similar Documents

Publication Publication Date Title
NZ594682A (en) Fully human antibodies specific to cadm1
MX2021007006A (es) Anticuerpo anti-calicreina-2 humanizado.
NZ743713A (en) Human immunodeficiency virus neutralizing antibodies
MX2019007848A (es) Anticuerpos anti-pd-1 y usos de los mismos.
PH12020551930A1 (en) Anti-sirpa antibodies and methods of use thereof
SG10201907161YA (en) Antibodies directed against lymphocyte activation gene 3 (lag-3)
PE20200294A1 (es) Anticuerpos que se unen especificamente a pd-1 y metodos de uso
MY192822A (en) An anti-ctla4 monoclonal antibody or antigen binding fragment thereof, a pharmaceutical composition and use
NZ594466A (en) Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies
MX2019011986A (es) Regiones constantes de igm humana modificadas para la modulacion de la funcion efectora de la citolisis dependiente de complemento referencia cruzada a solicitudes relacionadas.
NZ602780A (en) Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
SI2579894T1 (en) CGRP PROTITELESA
PE20141151A1 (es) Proteinas de union al antigeno cd27l
MX2021012997A (es) Anticuerpos anti-c5 humanizados bifuncionales y proteínas de fusión del factor h y usos de los mismos.
NZ595792A (en) Antibodies specific to cadherin-17
JOP20190103B1 (ar) شدفة Fab جديدة لجسم مضاد ضد MUC1 بشري
MX2017000615A (es) Anticuerpo anti-tie 2 humano novedoso.
MX2021002710A (es) Anticuerpos anti-c5 humanizados y usos de los mismos.
MX2020013324A (es) Anticuerpos anti proteína reguladora de señales beta 1 (sirp-beta1) y métodos de uso de los mismos.
MX2022001111A (es) Anticuerpo anti-pd-1 y uso farmaceutico del mismo.
NZ610091A (en) Antibodies
MX2019008989A (es) Anticuerpos anti-tnf, composiciones y metodos para el tratamiento de la artritis psoriasica activa.
MX2016008520A (es) Anticuerpo bdca-2 antihumano novedoso.
MX2021001516A (es) Uso del anticuerpo tim-3 en la preparacion de medicamentos para el tratamiento de tumores.
PH12018502293A1 (en) Humanized anti-basigin antibodies and the use thereof